| Document Number: QAP013.01 | Title: RISK MANAGEMENT PROGRAM CONFIDENTIAL INFORMATION VIKING THERAPEUTICS, INC. | Effective Date: 26Jun2024 |
| --- | --- | --- |
| Section: Quality Assurance | Supersedes Date: N/A |  |
| Subsection: Procedures | Page: 1 of 1 |  |
| CONTENTS |  |  |
| 1. Purpose |  | 3 |
| 2. Responsibilities |  | 3 |
| 3. | References |  | 5 |
| 4. Definitions |  | 5 |
| 5. | Procedure |  | 7 |
| 5.1. | Background |  | 7 |
|  | 5.2. Risk Management Plan | 8 |
|  | 5.3. Risk Management File |  | 10 |
|  | 5.4. | Hazard Analysis |  |  | 11 |
|  | 5.5. Criteria for Verification of Risk Controls | 11 |
| 5.6. | Risk Analysis |  | 11 |
| 5.6.1. | Risk Analysis Process | 11 |
| 5.6.2. Intended Use, Reasonably Foreseeable Misuse, and Identification of | Characteristics Related to the |  |
|  | Safety of the Combination Product | 12 |
| 5.6.3. | Identification of Hazards | 12 |
| 5.6.4. | Identification of Hazardous Situations | 13 |
| 5.6.5. | Identification of Harms | 13 |
| 5.6.6. | Reasonably Foreseeable Sequence of Events or Cause(s) | 13 |
| 5.7. Risk Estimation | 13 |  |
| 5.8. Risk Evaluation |  | 16 |
| 5.9. Risk Control | 16 |  |
|  | 5.9.1. | Risk Reduction |  | 16 |
|  | 5.9.2. | Risk Control Option Analysis | 17 |
| 5.9.3. | Implementation of Risk Control Measures. | 17 |
|  | 5.9.4. | Residual Risk Evaluation | 17 |
| 5.9.5. | Benefit-Risk Analysis | 18 |
|  | 5.9.6. | Risks Arising from Risk Control Measure(s) | 18 |
| 5.9.7. | Completeness of Risk Control | 18 |
| 5.10. | Evaluation of Residual Risk | 18 |
| 5.11. | Risk Management Report | 19 |
| 5.12. | Production and Post-Production Activities | 19 |
| 5.13. | Periodic Reviews | 20 |
| 6. | Appendices, Forms and Templates | 20 |
| 7. | Revision History |  | 20 |